Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review

Table 2 Studies comparing stereotactic body radiation therapy to other local treatments

Author	Yr	Type	Treat.	n	Size	mf	PT	CP class	f/u	Dose	1y-LC	1y-OS	tox.	Comment
Su et al[40]	2017	pm	SBRT	33 (45)	3.3 (NR) cm	36%	0%	A: 100%	42	42-48/3Fx	84%1	100%	nausea4	LC/OS NS
			OP	33 (45)	3.3 (NR) cm	30%	0%	A: 100%	44		72%1	97%	bleed./pain5
Wahl et al[19]	2016	retro	SBRT	63 (83)	2.2 (0.1-10) cm	29%	2 (0-7)2	A: 69%, B: 29%, C: 2%	13	30-50/3-5Fx	97%	74%	grade3+:3%	LC/OS NS
			RFA	161 (249)	1.8 (0.6-7) cm	32%	0 (0-7)2	A: 50%, B: 42%, C: 8%	20		84%	70%	grade3+:11%	> 2 cm LC sig↑ with SBRT
Sapir et al[20]	2018	retro	SBRT	125 (173)	2.3 (0.1-20.8) cm	NR	2 (NR)2	6 (5-9)3	12	30-50/3-5Fx	97%	75%	grade3+:8%	LC sig↑ with SBRT
			TACE	84 (84)	2.9 (0.7-15) cm	NR	0 (NR)2	6 (5-9)3	23		47%	74%	grade3+:13%	Tox sig↑ with TACE

¹Intrahepatic recurrence free survival;

²Number of prior treatments median (range);

³CP score median (range);

⁴All grades, significantly increased with SBRT;

⁵All grades, significantly increaesd with surgery.

treat.: Treatment; n: Number of patients (lesions); size: Lesion size median(range); cm: Centimeter diameter; mf: Multifokal; PT: Prior treatment; CP: Child-Pugh; f/u: Median follow-up in months; dose: Total dose in Gy; Fx: Number of fractions; 1y-LC: 1-year local control rate; 1y-OS: 1-year overall survival rate; tox: Toxicity, NS: Not significant; pm: Propensity score matched pair analysis; retro: Retrospective; bleed.: bleeding; sig: Significant; OP: Surgery; RFA: Radiofrequency ablation; TACE: Transarterial chemoablation; NR: Not reported.